Aberrant methylation of the cyclin D2 promoter in primary small cell, nonsmall cell lung and breast cancers

International Journal of Cancer

Volumn 107, Issue 3, 2003, Pages 341-345

  Virmani, Arvind ^a,b   Rathi, Asha ^a   Heda, Shashank ^a   Sugio, Kenji ^c   Lewis, Cheryl ^a   Tonk, Vijay ^d   Takahashi, Takashi ^e   Roth, Jack A ^f   Minna, John D ^a,b   Euhus, David M ^a,b   Gazdar, Adi F ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c KYUSHU UNIVERSITY   (Japan)

^d TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^e AICHI CANCER CENTER HOSPITAL   (Japan)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Breast cancer; Cyclin D2; Methylation; Nonsmall cell lung cancer (NSCLC); Small cell lung cancer (SCLC)

Indexed keywords

CYCLIN D2; DNA;

ARTICLE; BREAST CANCER; CONTROLLED STUDY; DNA METHYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; PRIORITY JOURNAL; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ADULT; AGED; AGED, 80 AND OVER; AZACITIDINE; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CYCLINS; DNA METHYLATION; FEMALE; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; PROMOTER REGIONS (GENETICS); RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 0142059070     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11393     Document Type: Article

References (49)

1. Morgan DO. Principles of CDK regulation. Nature 1995;374:131-4.
2. Peeper DS, Upton TM, Ladha MH, Neuman E, Zalvide J, Bernards R, DeCaprio JA, Ewen ME. Ras signalling linked to the cell-cyle machinery by the retinoblastoma protein. Nature 1997;386:177-81.
3. Tetsu O, McCormick F. Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999;398:422-6.
4. Meyyappan M, Atadja PW, Riabowol KT. Regulation of gene expression and transcription factor binding activity during cellular aging. Biol Signals 1996;5:130-8.
5. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 1995;9:1149-63.
6. Motokura T, Bloom T, Kim HG, Juppner H, Ruderman JV, Kronenberg HM, Arnold A. A novel cyclin encoded by a bcl1-linked candidate oncogene. Nature 1991;350:512-5.
7. Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, Schmidt EV. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 1994;369:669-71.
8. Hanna Z, Jankowski M, Tremblay P, Jiang X, Milatovich A, Francke U, Jolicoeur P. The Vin-1 gene, identified by provirus insertional mutagenesis, is the cyclin D2. Oncogene 1993;8:1661-6.
9. Resnitzky D, Gossen M, Bujard H, Reed SI. Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system. Mol Cell Biol 1994;14:1669-79.
10. Kato J, Matsushime H, Hiebert SW, Ewen ME, Sherr CJ. Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev 1993;7:331-42.
11. Gillett C, Fantl V, Smith R, Fisher C, Bartek J, Dickson C, Barnes D, Peters G. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 1994;54:1812-7.
12. Jiang M, Shao Z, Zhang Y. Study on p53, mdm-2 and p21WAF1 protein expression in ER-positive and ER-negative human breast cancer cell lines and its relation to biological features. Zhonghua Bing Li Xue Za Zhi 1997;26:327-30.
13. Buckley MF, Sweeney KJ, Hamilton JA, Sini RL, Manning DL, Nicholson RI, deFazio A, Watts CK, Musgrove EA, Sutherland RL. Expression and amplification of cyclin genes in human breast cancer. Oncogene 1993;8:2127-33.
14. Lukas J, Bartkova J, Welcker M, Petersen OW, Peters G, Strauss M, Bartek J. Cyclin D2 is a moderately oscillating nucleoprotein required for G1 phase progression in specific cell types. Oncogene 1995;10: 2125-34.
15. Tam SW, Shay JW, Pagano M. Differential expression and cell cycle regulation of the cyclin -dependent kinase 4 inhibitor p16Ink4. Cancer Res 1994;54:5816-20.
16. Sweeney KJ, Sarcevic B, Sutherland RL, Musgrove EA. Cyclin D2 activates Cdk2 in preference to Cdk4 in human breast epithelial cells. Oncogene 1997;14:1329-40.
17. Nacht M, Ferguson AT, Zhang W, Petroziello JM, Cook BP, Gao YH, Maguire S, Riley D, Coppola G, Landes GM, Madden SL, Sukumar S. Combining serial analysis of gene expression and array technologies to identify genes differentially expressed in breast cancer. Cancer Res 1999;59:5464-70.
18. Evron E, Umbricht CB, Korz D, Raman V, Loeb DM, Niranjan B, Buluwela L, Weitzman SA, Marks J, Sukumar S. Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation. Cancer Res 2001;61:2782-7.
19. Sicinski P, Donaher JL, Geng Y, Parker SB, Gardner H, Park MY, Robker RL, Richards JS, McGinnis LK, Biggers JD, Eppig JJ, Bronson RT, Elledge SJ, Weinberg RA. Cyclin D2 is an FSH-responsive gene involved in gonadal cell proliferation and oncogenesis. Nature 1996;384:470-4.
20. Baylin SB, Belinsky SA, Herman JG. Aberrant methylation of gene promoters in cancer-concepts, misconcepts, and promise. J Natl Cancer Inst 2000;92:1460-1.
21. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet 1999;21:163-7.
22. Girard L, Zochbauer-Muller S, Virmani AK, Gazdar AF, Minna JD. Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering. Cancer Res 2000;60:4894-906.
23. Herrmann BG, Frischauf AM. Isolation of genomic DNA. Methods Enzymol 1987;152:180-3.
24. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996;93:9821-6.
25. Evron E, Dooley WC, Umbricht CB, Rosenthal D, Sacchi N, Gabrielson E, Soito AB, Hung DT, Ljung B, Davidson NE, Sukumar S. Detection of breast cancer cells in ductal lavage fluid by methylation specific PCR. Lancet 2001;357:1335-6.
26. Renbaum P, Abrahamove D, Fainsod A, Wilson GG, Rottem S, Razin A. Cloning, characterization, and expression in Escherichia coli of the gene coding for the CpG DNA methylase from Spiroplasma sp. strain MQI(M.SssI). Nucleic Acids Res 1990;18:1145-52.
27. Chen XQ, Bonnefoi H, Pelte MF, Lyautey J, Lederrey C, Movarekhi S, Schaeffer P, Mulcahy HE, Meyer P, Stroun M, Anker P. Telomerase RNA as a detection marker in the serum of breast cancer patients. Clin Cancer Res 2000;6:3823-6.
28. Virmani AK, Rathi A, Sathyanarayana UG, Padar A, Huang CX, Cunningham HT, Farinas AJ, Milchgrub S, Euhus DM, Gilcrease M, Herman J, Minna JD, et al. Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas. Clin Cancer Res 2001;7:1998-2004.
29. Widschwendter M, Jones PA. DNA methylation and breast carcinogenesis. Oncogene 2002;21:5462-82.
30. Sherr CJ, Kato J, Quelle DE, Matsuoka M, Roussel MF. D-type cyclins and their cyclin-dependent kinases: G1 phase integrators of the mitogenic response. Cold Spring Harb Symp Quant Biol 1994;59: 11-9.
31. Ando K, Ajchenbaum-Cymbalista F, Griffin JD. Regulation of G1/S transition by cyclins D2 and D3 in hematopoietic cells. Proc Natl Acad Sci USA 1993;90:9571-5.
32. Matsushime H, Roussel MF, Ashmun RA, Sherr CJ. Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle. Cell 1991;65:701-13.
33. Won KA, Xiong Y, Beach D, Gilman MZ. Growth-regulated expression of D-type cyclin genes in human diploid fibroblasts. Proc Natl Acad Sci USA 1992;89:9910-4.
34. Schuuring E, Verhoeven E, Mooi WJ, Michalides RJ. Identification and cloning of two overexpressed genes, U21B31/PRAD1 and EMS1, within the amplified chromosome 11q13 region in human carcinomas. Oncogene 1992;7:355-61.
35. van Diest PJ, Michalides RJ, Jannink L, van der Valk P, Peterse HL, de Jong JS, Meijer CJ, Baak JP. Cyclin D1 expression in invasive breast cancer. Correlations and prognostic value. Am J Pathol 1997; 150:705-11.
36. Costello JF, Fruhwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao X, Wright FA, Feramisco JD, Peltomaki P, Lang JC, Schuller DE, Yu L, et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 2000;24:132-8.
37. Toyooka S, Toyooka KO, Maruyama R, Virmani A, Girard L, Miyajima K, Harada K, Ariyoshi Y, Takahashi T, Sugio K, Brambilla E, Gilcrease M, et al. DNA methylation profiles of lung tumors. Mol Cancer Therap 2001;1:61-7.
38. Piva R, Rimondi AP, Hanau S, Maestri I, Alvisi A, Kumar VL, del Senno L. Different methylation of oestrogen receptor DNA in human breast carcinomas with and without oestrogen receptor. Br J Cancer 1990;61:270-5.
39. Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E, Bussaglia E, Prat J, Harkes IC, Repasky EA, Gabrielson E, Schutte M, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 2000;92: 564-9.
40. Zochbauer-Muller S, Fong KM, Virmani AK, Geradts J, Gazdar AF, Minna JD. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 2001;61:249-55.
41. Heinen CD, Goss KH, Cornelius JR, Babcock GF, Knudsen ES, Kowalik T, Groden J. The APC tumor suppressor controls entry into S-phase through its ability to regulate the cyclin D/RB pathway. Gastroenterology 2002;123:751-63.
42. Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Pestell R, Ben-Ze'ev A. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci USA 1999;96:5522-7.
43. Bouchard C, Thieke K, Maier A, Saffrich R, Hanley-Hyde J, Ansorge W, Reed S, Sicinski P, Bartek J, Eilers M. Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27. Embo J 1999; 18:5321-33.
44. Perez-Roger I, Kim SH, Griffiths B, Sewing A, Land H. Cyclins D1 and D2 mediate myc-induced proliferation via sequestration of p27(Kip1) and p21(Cip1). Embo J 1999;18:5310-20.
45. Meyyappan M, Wong H, Hull C, Riabowol KT. Increased expression of cyclin D2 during multiple states of growth arrest in primary and established cells. Mol Cell Biol 1998;18:3163-72.
46. Wong DJ, Foster SA, Galloway DA, Reid BJ. Progressive region-specific de novo methylation of the p16 CpG island in primary human mammary epithelial cell strains during escape from M(0) growth arrest. Mol Cell Biol 1999;19:5642-51.
47. Belinsky SA, Nikula KJ, Palmisano WA, Michels R, Saccomanno G, Gabrielson E, Baylin SB, Herman JG. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci USA 1998;95:11891-6.
48. Kanai Y, Ushijima S, Tsuda H, Sakamoto M, Sugimura T, Hirohashi S. Aberrant DNA methylation on chromosome 16 is an early event in hepatocarcinogenesis. Jpn J Cancer Res 1996;87:1210-7.
49. Pogribny I, James S. De novo methylation of the p16(INK4A) gene in early preneoplastic liver and tumors induced by folate/methyl deficiency in rats. Cancer Lett 2002; 187:69.